MTOR and neoplasm: The pharmacological inhibition of glycosphingolipid biosynthesis using eliglustat resulted in the down-regulation of p-mTOR and its downstream effector p-4E-BP1, in RAC1A159V mutant tumor cells but not in WT cells (Fig. 5, K and L).